Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01625663 · ClinicalTrials.gov registry record
Heart and Muscle Metabolism in Barth Syndrome
A clinical trial of Barth Syndrome, sponsored by Duke University.
- Completed
- Registry status
- 64
- Enrollment target
- 1
- Study location
NCT01625663: Completed study of Barth Syndrome, sponsored by Duke University.
NCT01625663 is a study of Barth Syndrome that has completed, run by Duke University. The registered enrollment target is 64 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01625663, a study of Barth Syndrome, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
Barth syndrome (BTHS) is an X-linked disorder caused by abnormal cardiolipin metabolism and is characterized by skeletal and cardiomyopathy and high mortality rates. Through clinical metabolism and imaging studies and pluripotent stem cell induction and molecular techniques on skin biopsy samples, this project will produce novel translational information regarding the pathogenesis of BTHS, reveal potential targets for interventions and provide unique data regarding nutrient metabolism and abnormal cardiolipin and mitochondrial function. This project has the potential to provide information that could significantly improve morbidity and mortality in children and young adults with BTHS and may have relevance to other non-BTHS related conditions such as aging and adult heart failure.
Primary Outcome
Whole-body fatty acid oxidation rate will be measured by 13C-labeled fatty acid stable isotope tracer infusion and mass spectrometry
Conditions Studied
Study Locations (1)
Missouri
- Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2012-06 |
| Est. Completion | 2020-03-31 |
What the finished NCT01625663 record still lists
NCT01625663 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 64 participants, a relatively small participant target.
The record links to 1 condition, with Barth Syndrome appearing as the primary indexed condition, and to 0 interventions.
NCT01625663 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT01625663 about?
NCT01625663 is a clinical study titled "Heart and Muscle Metabolism in Barth Syndrome". Barth syndrome (BTHS) is an X-linked disorder caused by abnormal cardiolipin metabolism and is characterized by skeletal and cardiomyopathy and high mortality rates. Through clinical metabolism and imaging studies and pluripotent stem cell induction and molecular techniques on skin biopsy samples, t...
What is the current status of trial NCT01625663?
This trial is currently completed. The enrollment target is 64 participants. The study started on 2012-06. Estimated completion is 2020-03-31.
What conditions does trial NCT01625663 study?
This clinical trial studies the following conditions: Barth Syndrome.
Who is sponsoring clinical trial NCT01625663?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01625663 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Barth Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia